NCT03116516View on ClinicalTrials.gov

Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

May 26, 2017

Study Completion Date

May 26, 2017

Conditions
HypertensionHyperlipidemia
Interventions
DRUG

Temisartan/Amlodipine+Rosuvastatin

All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.

DRUG

YHP1604

All subjects will receive a single oral dose of YHP1604 administered in the morning.

Trial Locations (1)

561-712

Chonbuk National University Hospital, Jeonju

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03116516 - Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin | Biotech Hunter | Biotech Hunter